Related Experiment Video
Updated: Jun 26, 2026

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Role of HCN4 channel in preventing ventricular arrhythmia
Kazuo Ueda1, Yuji Hirano, Yasushi Higashiuesato
1Department of Molecular Pathogenesis, Tokyo Medical and Dental University, Tokyo, Japan.
Insights
The HCN4 channel, crucial for heart rate, may prevent bradycardia-induced ventricular arrhythmias. Mutations in HCN4 are linked to heart rhythm disorders, but its normal function appears protective.
Area of Science:
- Cardiac Electrophysiology
- Molecular Cardiology
- Computational Biology
Background:
- Bradycardia (slow heart rate) is a known trigger for ventricular arrhythmias, particularly in conditions like Brugada syndrome and long QT syndrome.
- The HCN4 channel is a key regulator of heart rate, and its dysfunction is associated with inherited arrhythmias and bradycardia.
- A patient with idiopathic ventricular tachycardia was found to have a genetic mutation in the HCN4 gene, predicted to result in a truncated channel.
Purpose of the Study:
- To investigate the role of the HCN4 channel in the context of ventricular arrhythmias.
- To explore the electrophysiological effects of HCN4 channel function during bradycardia.
Main Methods:
- A genetic analysis identified a 4 base-insertion mutation in the HCN4 gene splice donor site in a patient with idiopathic ventricular tachycardia.
- A computer simulation model was used to introduce the ventricular action potential of the I(f) current produced by HCN4.
- The model analyzed the behavior of the I(f) current during the plateau phase of the ventricular action potential.
Main Results:
- The I(f) current generated by the HCN4 channel exhibited a leaky outward current during the ventricular action potential plateau phase.
- These HCN4 channel currents were computationally shown to shorten action potential duration.
- The currents also appeared to prevent early after-depolarizations, a precursor to arrhythmias, during bradycardia.
Conclusions:
- The HCN4 channel's normal function, through the I(f) current, may play a protective role against bradycardia-induced ventricular arrhythmias.
- This suggests a potential dual role for HCN4: mutations leading to disease, but normal function being cardioprotective in specific contexts.
- Further research into HCN4 channel function could reveal new therapeutic targets for managing cardiac arrhythmias.
Abstract:
Bradycardia is a trigger of ventricular arrhythmias in patients with arrhythmia including Brugada syndrome and long QT syndrome. The HCN4 channel controls the heart rate, and its mutations predispose to inherited sick sinus syndrome and long QT syndrome associated with bradycardia. We found a 4 base-insertion at the splice donor site of the HCN4 gene in a patient with idiopathic ventricular tachycardia, which was supposed to generate a truncated channel. To investigate the role of the HCN4 channel in ventricular arrhythmia, we introduced a ventricular action potential of I(f) channel produced by HCN4 in a computer simulation model and found that the I(f) channel generated a leaky outward current during the plateau phase of ventricular action potential. Currents through the I(f) channel were suggested to contribute to the shortening of the action potential duration and the prevention of early after-depolarization in bradycardia. These observations suggested that the HCN4 channel played a preventive role in triggering bradycardia-induced ventricular arrhythmias.
Related Concept Videos
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Cardiomyopathy III: Hypertrophic Cardiomyopathy

